Structure Therapeutics Inc. (GPCR)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGM
22.19 USD
+0.31
(1.417%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:17 a.m. EDT
The investment case here is fundamentally broken despite the hype surrounding its obesity pipeline. The company is burning cash aggressively with negative free cash flow and operating cash flow, while returning capital to shareholders via insider sales rather than dividends. The balance sheet is a facade; while debt is low, the lack of revenue and negative returns on equity signal a business that cannot yet sustain itself without constant capital infusion. The market has already priced in the potential success of the GLP-1 data, evidenced by the stock trading near its 52-week low despite 'strong buy' analyst ratings which often lag reality in biotech. The options market confirms this skepticism, with traders stacking heavy put protection at strikes significantly above the current price, betting on further deterioration or a failed catalyst. This is a speculative gamble on a future blockbuster, not a sound investment vehicle. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.227127 |
| AutoETS | 0.229076 |
| AutoARIMA | 0.229111 |
| AutoTheta | 0.249004 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 78.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.177 |
| Excess Kurtosis | -0.95 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.46 |
| Market Cap | 1,582,365,696 |
| Forward P/E | -10.50 |
| Beta | -1.37 |
| Website | https://structuretx.com |
As of Oct. 10, 2026, 9:17 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts (strikes 32.5, 35, 40, 55) compared to negligible call volume. While there is some speculative call buying at distant strikes (100, 110) suggesting a binary event hope, the overwhelming capital allocation is in put writing and buying, indicating a consensus expectation of further price weakness or a 'sell the news' scenario following recent clinical data.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.20087653 |
| Address1 | 601 Gateway Boulevard |
| Address2 | Suite 900 |
| All Time High | 94.9 |
| All Time Low | 13.22 |
| Ask | 64.0 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 1,533,860 |
| Average Daily Volume3 Month | 1,021,968 |
| Average Volume | 1,021,968 |
| Average Volume10Days | 1,533,860 |
| Beta | -1.368 |
| Bid | 36.54 |
| Bid Size | 2 |
| Book Value | 19.018 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 22.19 |
| Current Ratio | 20.753 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 22.615 |
| Day Low | 21.81 |
| Debt To Equity | 0.46 |
| Display Name | Structure Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -265,787,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.925 |
| Enterprise Value | 245,935,728 |
| Eps Current Year | -1.61032 |
| Eps Forward | -2.11297 |
| Eps Trailing Twelve Months | -3.03 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 40.9584 |
| Fifty Day Average Change | -18.7684 |
| Fifty Day Average Change Percent | -0.4582308 |
| Fifty Two Week Change Percent | -20.087654 |
| Fifty Two Week High | 94.9 |
| Fifty Two Week High Change | -72.71 |
| Fifty Two Week High Change Percent | -0.7661749 |
| Fifty Two Week Low | 21.55 |
| Fifty Two Week Low Change | 0.6400013 |
| Fifty Two Week Low Change Percent | 0.029698437 |
| Fifty Two Week Range | 21.55 - 94.9 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,675,434,600,000 |
| Float Shares | 55,462,667 |
| Forward Eps | -2.11297 |
| Forward P E | -10.501805 |
| Free Cashflow | -119,056,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 281 |
| Fullday Change | -0.09000015 |
| Fullday Change Percent | -0.40558878 |
| Fullday Price | 22.1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.031070001 |
| Held Percent Institutions | 0.97666 |
| Implied Shares Outstanding | 71,309,857 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-02-03 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. |
| Long Name | Structure Therapeutics Inc. |
| Market | us_market |
| Market Cap | 1,582,365,696 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1673457818 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -214,835,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,563,589,371 |
| Number Of Analyst Opinions | 15 |
| Open | 21.89 |
| Operating Cashflow | -220,292,992 |
| Operating Margins | 0.0 |
| Phone | 650 457 1978 |
| Pre Market Change | -0.09000015 |
| Pre Market Change Percent | -0.40558878 |
| Pre Market Price | 22.1 |
| Pre Market Time | 1,792,148,418 |
| Previous Close | 21.88 |
| Price Eps Current Year | -13.77987 |
| Price Hint | 2 |
| Price To Book | 1.1667894 |
| Profit Margins | 0.0 |
| Quick Ratio | 20.309 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.310001 |
| Regular Market Change Percent | 1.41683 |
| Regular Market Day High | 22.615 |
| Regular Market Day Low | 21.81 |
| Regular Market Day Range | 21.81 - 22.615 |
| Regular Market Open | 21.89 |
| Regular Market Previous Close | 21.88 |
| Regular Market Price | 22.19 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 1,151,620 |
| Return On Assets | -0.14946 |
| Return On Equity | -0.20206 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 71,309,857 |
| Shares Percent Shares Out | 0.10569999 |
| Shares Short | 7,540,480 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,854,907 |
| Short Name | Structure Therapeutics Inc. |
| Short Percent Of Float | 0.14479999 |
| Short Ratio | 5.44 |
| Source Interval | 15 |
| State | CA |
| Symbol | GPCR |
| Target High Price | 145.0 |
| Target Low Price | 70.0 |
| Target Mean Price | 105.78333 |
| Target Median Price | 101.0 |
| Total Cash | 1,342,658,048 |
| Total Cash Per Share | 18.829 |
| Total Debt | 6,228,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.03 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 51.91555 |
| Two Hundred Day Average Change | -29.72555 |
| Two Hundred Day Average Change Percent | -0.5725751 |
| Type Disp | Equity |
| Volume | 1,151,620 |
| Website | https://structuretx.com |
| Zip | 94,080 |